Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.89 +0.89 (+2.12%)
Streaming Delayed Price Updated: 2:47 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript
SUPN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
Supernus Pharmaceuticals shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session. 
Via Talk Markets
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Via AB Newswire
Supernus Pharmaceuticals: Q3 Earnings Insights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Why Supernus' Acquisition of Adamas Is a Smart Move
Adamas looks like a good fit for Supernus. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
Via Talk Markets
Topics Stocks
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has... 
Via Benzinga
Topics Stocks
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the... 
Via Benzinga
Topics Stocks
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. 
Via InvestorPlace
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal... 
Via Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What... 
Via Benzinga
Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript
SUPN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Supernus Pharmaceuticals Inc (SUPN) Q1 2021 Earnings Call Transcript
SUPN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning session, 226 stocks hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was NVIDIA (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.